Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability
Yan Feng, Jaewon Lee, Liping Yang, Mary Beth Hilton, Karen Morris, Steven Seaman, Veera V. Shivaji R. Edupuganti, Kuo-Sheng Hsu, Christopher M. Dower, Guojun Yu, Daeho So, Pradip Bajgain, Zhongyu Zhu, Dimiter S. Dimitrov, Nimit L. Patel, Christina M. Robinson, Simone Difilippantonio, Marzena Dyba, Amanda Corbel, Falguni Basuli, Rolf E. Swenson, Joseph D. Kalen, Sreedhar Reddy Suthe, Myer Hussain, James S. Italia, Colby A. Souders, Ling Gao, Martin J. Schnermann, Brad St. Croix
Abstract
CD276/B7-H3 represents a promising target for cancer therapy based on widespread overexpression in both cancer cells and tumor-associated stroma. In previous preclinical studies, CD276 antibody-drug conjugates (ADCs) exploiting a talirine-type pyrrolobenzodiazepine (PBD) payload showed potent activity against various solid tumors but with a narrow therapeutic index and dosing regimen higher than that tolerated in clinical trials using other antibody-talirine conjugates. Here, we describe the development of a modified talirine PBD-based fully human CD276 ADC, called m276-SL-PBD, that is cross-species (human/mouse) reactive and can eradicate large 500–1,000-mm3 triple-negative breast cancer xenografts at doses 10- to 40-fold lower than the maximum tolerated dose. By combining CD276 targeting with judicious genetic and chemical ADC engineering, improved ADC purification, and payload sensitivity screening, these studies demonstrate that the therapeutic index of ADCs can be substantially increased, providing an advanced ADC development platform for potent and selective targeting of multiple solid tumor types.